⌕
Arrowhead Pharmaceuticals · ARWR · Nasdaq
Tenet 33 · Weak
Compare
$42.99−2.76%At closeTenet 33 · Weak
$42.99−1.22 (−2.76%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arrowhead Pharmaceuticals (ARWR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

18 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 46% below its peak, net margin −160.6%. Worth your attention in FY26: Share count (+34.3%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY22–FY26
Revenue ($M)▼45.6%
450.8
FY22→FY26CAGR +16.7%/yr
Net income ($M)▼44302.6%
−724.2
one-off year: see footnoteCAGR —
Free cash flow ($M)—
−283.9
FY22→FY26CAGR —
Diluted EPS▼51000.0%
−5.11
FY22→FY26CAGR —
What the receipts whisper · what a headline number hides
Share count
+34.3%

105.4mn → 141.6mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.

Capex
$12.0M

−47.1% YoY in FY26 · 2.7% of revenue.

Returns vs FCF
n/m

$56.0M returned vs $−283.9M of FCF in FY26. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($M)450.8Revenue−1.8COGS−739.1R&D−202.0SG&A−707.2Op income−17.0Tax & other−724.2Net income

-161¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Operating Net
20151050%sector median net margin ~3%FY22FY26

Net margin -160.6% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY22–FY26 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY26FY25FY24FY23FY22YoYCAGR 22→26
Revenue & profitability
Revenue
450.8450.8829.47.1240.7243.2▼45.6%+16.7%
Cost of revenue
1.81.80.00.00.00.0——
Gross profit
——A—B—B—B—B——
Research & development
739.1739.1607.2505.9353.2297.3▲21.7%+25.6%
Selling, general & admin
202.0202.0123.998.892.5124.4▲63.0%+12.9%
Total operating expenses
1,156.21,156.2731.1604.6445.7421.7▲58.1%+28.7%
Operating incomefeeds ROC rank
−707.2−707.298.3−601.1−205.0−178.5——
Other income, net
−16.7−16.7−46.8−11.4−1.55.8——
Pretax income
−723.9−723.951.5−612.5−206.5−172.7——
Income tax
−6.8−6.821.4−2.82.83.8——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−724.2−724.2−1.6−599.5−205.3−176.1▼44302.6%—
Per share
Diluted EPSbuyback-sensitive
−5.11−5.11−0.01−5.00−1.92−1.67——
Diluted shares (mn)
141.63141.63133.76119.78106.75105.43▲5.9%+7.7%
Margins
Gross margin98th pct in Healthcare
——A—B—B—B—B——
Operating margin
−156.9%−156.9%11.9%−8463.5%−85.2%−73.4%▼168.7pp−83.5pp
Net margin8th pct in Healthcare
−160.6%−160.6%−0.2%−8441.2%−85.3%−72.4%▼160.4pp−88.3pp
† TTM = fiscal 2026, through 2026-09-30. The newest fiscal year already covers the newest quarter we hold, so the trailing twelve months are that year and this column repeats its figures.FY25 effective tax rate was 42% vs a 0% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.B Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY10 – FY21 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-11-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Arrowhead Pharmaceuticals' revenue last fiscal year?

Arrowhead Pharmaceuticals reported revenue of $450.8M in fiscal 2026, down 45.6% from fiscal 2025.

What was Arrowhead Pharmaceuticals' net income?

Arrowhead Pharmaceuticals reported net income of −$724.2M in fiscal 2026, a net margin of −160.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.